Regulatory File Review Sample Clauses

Regulatory File Review. The Contractor must perform a regulatory file review to identify any agency actions filed against the site that may indicate contamination of the subject property, including, but not limited to, the following tasks: • Examination of hazardous waste (Superfund) sites on the USEPA-National Priority List (NPL) that are located within a one-half (½) mile radius of the site; • Examination of USEPA-Comprehensive Environmental Response, Comprehensive Liability Information System (CERCLIS) inventory of potentially hazardous waste sites under investigation within a one-half-mile radius of the site; • Examination of Virginia Department of Waste Management's inventory of Permitted Solid Waste Facilities; • Review of Virginia Department of Waste Management's Hazardous Waste Handlers List; • Review of the Virginia State Water Control Board files for the property and adjacent properties; • Review of the Virginia State Underground Storage Tank (UST) Database; • Review of Virginia State Water Control Board Leaking Underground Storage Tank (LUST) Database for subject and adjacent properties; • Review of State Health Department records relative to surface and ground water for the site; • Review of registry of underground storage tanks and reported hazardous materials incidents available through the Fire Prevention Division of the Fire Department; • Review of other available data relating to prior or current site usage; • Review of Corps of Engineers, FEMA, and other regulatory agencies files for the site.
Sample 1
AutoNDA by SimpleDocs
Regulatory File Review. In order to obtain historical regulatory documents for the facility and neighboring Conbraco Industries facility, H&H and Xxxxxx Xxxxxx will conduct a file review at the North Carolina Department of Environment and Natural Resources (DENR) offices. The file review will be used to obtain information concerning the areas of types of groundwater impacts at the Conbraco facility and additional information concerning the site in DENR's files. The results of the file review may indicate that a revision to the analytes or locations of samples is warranted. If this is the case, then we will notify you of the proposed changes prior to sampling activities.
Sample 1

Related to Regulatory File Review

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Time is Money Join Law Insider Premium to draft better contracts faster.